





Rychlé odkazy
Odkazy na členy
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
PPTA Announces Changes to Global Executive Board and European Board Leadership
PPTA Announces Changes to Global Executive Board and European Board Leadership
Kategorie
Odběr a výroba plazmy
Learn more about plasma collection and discover certified plasma centers near you.
Časopis The Source
Subscribe to the international magazine of the plasma protein therapeutics industry.
Informační listy
Fact sheets provide additional information about the global plasma protein therapeutics industry.
Často kladené otázky o plazmě
Get answers about plasma therapies and the processes surrounding donation and collection procedures.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Oct 28, 2026
Maintaining Immunoglobulins on the Union List of Critical Medicines to Safeguard Patient Access
As the review of the Union List of Critical Medicines (ULCM) approaches its conclusion, the Plasma Protein Therapeutics Association (PPTA) strongly supports maintaining human normal immunoglobulins (IG) on the Union list1 as they are lifesaving, irreplaceable treatments of human origin facing ongoing supply challenges. Maintaining IG on the Union list supports the EU’s broader agenda to strengthen the resilience, security and sustainability of medicines supply as well as safeguard reliable access for patients across Europe.
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6ae22ea3cac65bcf56c49109_FINAL%20PPTA%20statement%20on%20Union%20List%20of%20Critical%20Medicines_28.10.2026.pdf
Oct 28, 2026
Maintaining Immunoglobulins on the Union List of Critical Medicines to Safeguard Patient Access
As the review of the Union List of Critical Medicines (ULCM) approaches its conclusion, the Plasma Protein Therapeutics Association (PPTA) strongly supports maintaining human normal immunoglobulins (IG) on the Union list1 as they are lifesaving, irreplaceable treatments of human origin facing ongoing supply challenges. Maintaining IG on the Union list supports the EU’s broader agenda to strengthen the resilience, security and sustainability of medicines supply as well as safeguard reliable access for patients across Europe.
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6ae22ea3cac65bcf56c49109_FINAL%20PPTA%20statement%20on%20Union%20List%20of%20Critical%20Medicines_28.10.2026.pdf
No results found

